Commentary on the European Medicines Agency's extended mandate: Protecting public health in times of crisis and improving availability of medicines and medical devices

被引：2

|

作者：

Abed, Inga ^{[1
]}

Gonzalez-Quevedo, Rosa ^{[1
]}

Mura, Manuela ^{[2
]}

Dias, Monica ^{[3
]}

da Rocha Dias, Silvy ^{[4
]}

Garcia Burgos, Juan ^{[1
]}

机构：

[1] European Med Agcy, Publ & Stakeholders Engagement, Amsterdam, Netherlands

[2] European Med Agcy, Hlth Threats & Vaccines Strategy, Amsterdam, Netherlands

[3] European Med Agcy, Supply & Avilbil Med & Devices, Regulatory Sci & Innovat Task Force, Amsterdam, Netherlands

[4] European Med Agcy, Expert Panels & Groups, Committees & Qual Assurance, Amsterdam, Netherlands

来源：

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 2023年 / 89卷 / 01期

关键词：

D O I：

10.1111/bcp.15567

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

收藏

页码：5 / 10

页数：6

相关论文

共 13 条

[11] Patient Access in 14 High-Income Countries to New Antibacterials Approved by the US Food and Drug Administration, European Medicines Agency, Japanese Pharmaceuticals and Medical Devices Agency, or Health Canada, 2010-2020
Outterson, Kevin
Orubu, Ebiowei S. F.
Rex, John
Ardal, Christine
Zaman, Muhammad H.
CLINICAL INFECTIOUS DISEASES, 2022, 74 (07) : 1183 - 1190
[12] A widening authority-legitimacy gap in EU regulatory governance? An experimental study of the European Medicines Agency's legitimacy in health security regulation
Rimkute, Dovile
Mazepus, Honorata
JOURNAL OF EUROPEAN PUBLIC POLICY, 2023, 30 (07) : 1406 - 1430
[13] Qualification opinion of novel methodologies in the predementia stage of Alzheimer's disease: Cerebro-spinal-fluid related biomarkers for drugs affecting amyloid burden - Regulatory considerations by European Medicines Agency focusing in improving benefit/risk in regulatory trials
Isaac, Maria
Vamvakas, Spiros
Abadie, Eric
Jonsson, Bertil
Gispen, Christine
Pani, Luca
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2011, 21 (11) : 781 - 788